KYG4672N1198
© Globe Newswire
14.01.2026
13
LISTED
HKSE
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
News Preview
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment —...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
13
LISTED
HKSE
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
News Preview
— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — ...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
13
LISTED
HKSE
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-li...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
30.12.2025
13
LISTED
HKSE
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
News Preview
— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 —...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
29.12.2025
13
LISTED
HKSE
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
News Preview
— NDA supported by results from a Phase II registration trial in China —...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
13
LISTED
HKSE
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
News Preview
— First-in-human trial of candidate from the next-generation ATTC platform —...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
13
LISTED
HKSE
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.11.2025
13
LISTED
HKSE
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Asia Congress 2025, taking pla...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
13
LISTED
HKSE
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with epidermal growth fact...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
13
LISTED
HKSE
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
News Preview
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2025
13
LISTED
HKSE
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
News Preview
— First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities —...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
13
LISTED
HKSE
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with ef...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
13.10.2025
13
LISTED
HKSE
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
News Preview
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
13
LISTED
HKSE
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2025, taking place on...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2025
13
LISTED
HKSE
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
News Preview
— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 — — HUTCHMED will host in-person presentation and online webinar on Friday, October 31 —...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
13
LISTED
HKSE
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2025 World Conference on Lung Cancer (“WCLC”) taking place on September 6-9,...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
13
LISTED
HKSE
HUTCHMED Announces Appointment of Acting Chief Executive Officer
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Dir...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
13
LISTED
HKSE
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung c...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
13
LISTED
HKSE
HUTCHMED to Announce 2025 Half-Year Financial Results
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Tim...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
13
LISTED
HKSE
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
News Preview
— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
13
LISTED
HKSE
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients wit...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
13
LISTED
HKSE
HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
News Preview
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2025
13
LISTED
HKSE
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clin...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
13
LISTED
HKSE
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
13
LISTED
HKSE
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
News Preview
HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.03.2025
13
LISTED
HKSE
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
News Preview
— First and only EZH2 inhibitor approved by the NMPA —...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
13
LISTED
HKSE
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
News Preview
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting —...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.03.2025
13
LISTED
HKSE
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
News Preview
65% oncology products revenue growth drove profitable operation and supported new ATTC platform 65% oncology products revenue growth drove profitable operation and supported new ATTC platform...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.03.2025
13
LISTED
HKSE
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating fruquintinib in combination with sintilimab as second-line tre...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
13
LISTED
HKSE
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of its a Phase II trial of fanregratinib (HMPL-453) for intrahepatic cholangiocarcinoma (“IHCC”) patients with fibroblast growth factor receptor (“FGFR...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
13
LISTED
HKSE
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6,...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
13
LISTED
HKSE
HUTCHMED to Announce 2024 Final Results
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Tim...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
13
LISTED
HKSE
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
News Preview
— Indication expands to include treatment-naïve patients —...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.01.2025
13
LISTED
HKSE
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epiderma...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.01.2025
13
LISTED
HKSE
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
News Preview
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.12.2024
13
LISTED
HKSE
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
News Preview
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe —...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2024
13
LISTED
HKSE
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savo...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
13
LISTED
HKSE
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
News Preview
— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor —...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.11.2024
13
LISTED
HKSE
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.11.2024
13
LISTED
HKSE
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
News Preview
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 —...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2024
13
LISTED
HKSE
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
13
LISTED
HKSE
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
News Preview
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds discovered by HUTCHMED will be presented at the Ameri...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
13
LISTED
HKSE
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
News Preview
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — — US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
13
LISTED
HKSE
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
News Preview
— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer —...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
13
LISTED
HKSE
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
News Preview
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer —...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2024
13
LISTED
HKSE
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on Lung Cancer (“WCLC24”) in San Diego, USA, and the Eur...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
13
LISTED
HKSE
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastri...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.08.2024
13
LISTED
HKSE
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion leader in immune thrombocytopenia (“ITP”), to discuss the treatment landscape of ITP via webcast on Wednesday, A...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2024
13
LISTED
HKSE
HUTCHMED Reports 2024 Interim Results and Provides Business Updates
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2024 and provides updates on key clinical and commercial developments....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.07.2024
13
LISTED
HKSE
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) has been accepted for review an...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
13
LISTED
HKSE
HUTCHMED to Announce 2024 Half-Year Financial Results
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kon...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2024
13
LISTED
HKSE
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
News Preview
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
13
LISTED
HKSE
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
News Preview
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
13
LISTED
HKSE
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
News Preview
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.06.2024
13
LISTED
HKSE
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31, 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
13
LISTED
HKSE
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
News Preview
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.05.2024
13
LISTED
HKSE
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
News Preview
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) Annual Meeting, t...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.05.2024
13
LISTED
HKSE
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:-...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.05.2024
13
LISTED
HKSE
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
News Preview
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-30...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2024
13
LISTED
HKSE
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
News Preview
— Almost half a million people diagnosed each year across the globe —...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
